Ocugen(US:OCGN) ZACKS·2026-03-04 15:26分组1 - Ocugen reported a quarterly loss of $0.06 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.05 per share a year ago [1] - The company posted revenues of -$0.19 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 112.87%, and down from $0.76 million year-over-year [2] - Over the last four quarters, Ocugen has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] 分组2 - Ocugen shares have increased by approximately 37.8% since the beginning of the year, while the S&P 500 has declined by 0.4% [3] - The company's earnings outlook, including current consensus earnings expectations, will be crucial for future stock performance [4] - The current consensus EPS estimate for the coming quarter is -$0.07 on $1 million in revenues, and -$0.26 on $5.7 million in revenues for the current fiscal year [7] 分组3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 44% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ocugen's stock performance [5][6]